Inactive Instrument

LOCT WALK Stock Nasdaq

LWACU

US54015L3015

Analysts' recommendations: LOCT WALK

24/08/23	HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	MT
26/05/23	Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	MT
10/05/23	Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	MT
09/03/23	Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	MT
09/01/23	JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	MT

More recommendations

Locust Walk Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company focuses to identify and acquire a business, focusing on the healthcare or healthcare related industries in the United States and Europe. The Company has no business operations and has no revenues.

Employees

Sector

More about the company

Market Cap	940 827.08 761.74 712.68 1.33K 88.72K 1.36K 9.15K 3.54K 43.74K 3.53K 3.45K 152K	P/E 2022	-0.78x	P/E 2023	-0.71x
Enterprise Value	2.18M 1.91M 1.76M 1.65M 3.09M 205M 3.15M 21.17M 8.19M 101M 8.17M 7.99M 352M	EV / Sales 2022	3,344,920x	EV / Sales 2023	-
Free-Float	-	Yield 2022 *	-	Yield 2023	-

10/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
08/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI
02/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index	CI
24/06/24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
24/06/24	Top Midday Decliners	MT
24/06/24	EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	MT
24/06/24	EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer	CI
24/06/24	Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations	CI
24/06/24	Effector Therapeutics, Inc. Announces Director Resignations	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
20/05/24	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	CI
09/05/24	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

13/08/24	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer	AQ
26/06/24	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	PU
24/06/24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	AQ
04/04/24	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	AQ
05/02/24	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ

	2022	2023
Net sales	3.55 3.13 2.88 2.69 5.04 335.35 5.14 34.57 13.37 165.34 13.34 13.05 574.8	-
Net income	-22.66M -19.94M -18.37M -17.18M -32.17M -2.14B -32.82M -221M -85.3M -1.05B -85.1M -83.24M -3.67B	-35.81M -31.51M -29.02M -27.15M -50.84M -3.38B -51.85M -348M -135M -1.67B -134M -132M -5.79B
Net Debt	-6.03M -5.3M -4.89M -4.57M -8.56M -569M -8.73M -58.66M -22.69M -281M -22.64M -22.14M -975M	2.18M 1.91M 1.76M 1.65M 3.09M 205M 3.15M 21.16M 8.19M 101M 8.17M 7.99M 352M

LOCT WALK Stock Nasdaq

Stocks

LWACU

US54015L3015

Valuation: LOCT WALK

Latest news : LOCT WALK

Analysts' recommendations: LOCT WALK

Press Releases: LOCT WALK

Quotes and Performance

Financials

Company Profile